End-of-day quote
Korea S.E.
06:00:00 2024-05-30 pm EDT
5-day change
1st Jan Change
6,000
KRW
-0.83%
+9.49%
-12.79%
Mar. 27
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
CI
Mar. 18
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
CI
Sales 2022
6.5B
4.72M
Sales 2023
7.32B
5.31M
Capitalization
73.46B
53.33M
Net income 2022
-4.49B
-3.26M
Net income 2023
-4.49B
-3.26M
EV / Sales 2022
10.5
x
Net cash position
2022
835M
606K
Net Debt
2023
1.82B
1.32M
EV / Sales 2023
10.3
x P/E ratio 2022
-15.4
x
P/E ratio 2023
-16.4
x
Employees
-
Yield 2022 *
-
Yield 2023
-
Free-Float
53.77%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
Mar. 26
CI
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
Mar. 17
CI
PanGen Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-12
CI
PanGen Biotech Inc. announced that it has received KRW 3.2 billion in funding from Eugene Investment & Securities Co.,Ltd., Samsung Securities Co., Ltd.
23-04-19
CI
PanGen Biotech Inc. announced that it expects to receive KRW 3.2 billion in funding from Eugene Investment & Securities Co.,Ltd., Samsung Securities Co., Ltd.
23-04-17
CI
CrystalGenomics, Inc. agreed to acquire 20.43% stake in PanGen Biotech Inc. from the group of shareholders for approximately KRW24 billion.
22-11-21
CI
PanGen Biotech Inc. announced that it has received KRW 9.99998571 billion in funding from Huons Co., Ltd. and another investor
21-06-10
CI
PanGen Biotech Inc. announced that it expects to receive KRW 9.99998571 billion in funding from Huons Co., Ltd., and another investor
21-06-02
CI
Huons Lab Forms Partnership with Pangen Biotech to Co-Develop Human Genetic Recombinant Hyaluronidase
19-12-15
CI
PanGen Biotech Inc.(KOSDAQ:A222110) dropped from S&P Global BMI Index
19-09-23
CI
CCM Duopharma Biotech Berhad completed the acquisition of 8.4% stake in PanGen Biotech Inc. from Chemical Company of Malaysia Berhad.
18-06-28
CI
CCM Duopharma Biotech Berhad entered into agreement to acquire PanGen Biotech Inc. from Chemical Company of Malaysia Berhad for KRW 16.4 billion.
18-04-12
CI
Chemical Companies In Talks To Sell Non Core Assets
18-03-02
CI
PanGen Biotech Inc. announced that it has received KRW 18 billion in funding
18-02-20
CI
PanGen Biotech Inc. announced that it expects to receive KRW 18 billion in funding
18-02-18
CI
More news
1 day -0.83%
1 week +9.49%
1 month +0.84%
3 months +2.74%
6 months +6.57%
Current year -12.79%
More quotes
Managers
Title Age Since
Chief Executive Officer
63
10-01-28
Director of Finance/CFO
58
10-11-30
Chief Tech/Sci/R&D Officer
54
10-01-28
Members of the board
Title Age Since
Director/Board Member
60
-
Chief Executive Officer
63
10-01-28
58
-
More insiders
Date
Price
Change
Volume
24-05-31
6,000
-0.83%
8,669
24-05-30
6,050
+6.14%
15,014
24-05-29
5,700
+2.33%
3,121
24-05-28
5,570
+4.31%
6,445
24-05-27
5,340
-2.55%
18,388
End-of-day quote
Korea S.E., May 30, 2024
More quotes
Pangen Biotech Inc. is a Korea-based company primarily engaged in the bio pharmaceuticals development technology transfer services. The Company mainly provides contract services for the manufacture of bio pharmaceuticals, bio pharmaceuticals development technology transfer services for the manufacture of Chinese hamster ovary (CHO) cell lines and the process of products and gains royalty from the services. The Company also provides reagents which are used for the development of bio pharmaceuticals. In addition the Company is also engaged in the development of bio pharmaceuticals such as Biosimilar EPO, Recombinant Factor VIII and Biosimilar G-CSF. The Company provides its services within domestic market and to overseas markets such as China, India, Mexico, America and Europe.
More about the company
1st Jan change
Capi.
-12.79% 49.52M +43.36% 54.63B -5.31% 39.92B +14.75% 26.86B -12.56% 26.22B -22.45% 18.78B +25.12% 12.21B +0.04% 12.16B +26.04% 11.94B -11.83% 10.74B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1